On March 3rd, the MCCI held an online investment conference on BioMedTech, organized jointly with the Moscow City Innovation Agency and the Investors' Club.
Recall that a series of investment sessions, each of which is dedicated to a specific industry, is held by the MCCI in order to develop innovative businesses in the capital. Actively growing startups that have undergone the process of acceleration, have received pilot launches with a business or have already received initial investments, presenting their projects to investors and the required expertise.
“We are very gratified that we have the opportunity to help projects that pass ”The Moscow accelerator and pilot testing,” said Mr. Artem Dalevich, the Vice President of the MCCI, opening the event.
Mr. Artemiy Tatarintsev presented to the audience the project "Immunomics" - (“Immynomika”) the creation of platforms, based on gene technologies for screening potential means of specific chemotherapy for the new Coronavirus infection (COVID-19) and other socially significant viral infections (for example, HIV, herpes and all applied viruses affecting lipid membranes.
Mr. Igor Romanenko spoke about the “Hippocrates” project - a digital store of clinical questionnaires and algorithms for diagnosing diseases. According to the speaker, doctors at the reception for various reasons often miss "anamnestic, as well as clinical information about the disease, the symptoms of dangerous diseases." As a result, up to 30% of diagnoses are made incorrectly, and up to 60% of them need to be clarified. With the help of "Hippocrates", the patient, before visiting the doctor, must fill out a specific form, answering a number of questions, which will facilitate the subsequent diagnosis. "Hippocrates" allows to increase the early detection of diseases by 15%, to reduce medical errors in diagnostics by 12% and save the admission time by up to 30%.
Mr. Ilya Fedorinin presented the digital medical platform "Synapse" for data collection, which allows "to reduce the cost of structuring medical data without high costs." The service is required for predictive analytics, clinical practice analysis, controlled data collection, etc.
Mr. Maxim Skulachev, the CEO of “Mitotech” presented “Mitotech-19”’s - "precision delivery of vaccine of high effectiveness " for saving lives in critical situations, including injuries, sepsis, ischemic lesions, severe forms of COVID-19. The drug is in the final stage of preclinical studies.
“Due to improper prescription of drugs, negative drug reactions occur annually in the world - up to 2 million cases, of which 250 thousand end up tragically,” said the next speaker, Ms. Alla Panchenko, the Development Director for PharmacoGenomeX2. She introduced the audience to the support system, designed for coming up with the optimal drug dosage regimen.The company, PharmacoGenomeX2, specialises in providing the personalisation of treatment, based on genetic testing for almost all drug categories.
Mr. Alexander Oksanenko introduced the audience to the “PathVision.ai” - "an assistant for automated diagnostics of prostate cancer based on artificial intelligence technology." According to the speaker, prostate cancer is the second leading cause of death in men. The new system significantly improves the diagnostic process: the digital version of the slide, obtained during the study, is sent for processing by artificial intelligence, which will provide the doctor with a complete slide markup and a preliminary morphological conclusion. The product also includes a web-based layout for slides and a histology laboratory automation platform.
Ms. Olga Oshurkova (The owner and CEO of the “DivaOra Group LLC” spoke about the development of the first mobile eye trainer “Cure. play” (“Lechi.igraI”), which allows to maintain and improve vision for adults and children and, in many cases, avoid surgery.
According to the next speaker, Dr. Alexander Grigoriev, every fourth diagnosis of ENT’s diseases is currently inaccurate. He presented the audience with the system of diagnostics and support for making medical decisions for “ENT diseases Pirogov.ai”, based on endoscopic photographs and video images with the accuracy of 95%. According to him, the system can be used not only by the narrow segment of the ENT specialists, but also by general practitioners.
Mr. Oleg Evseenkov, the CEO of the “Polymorph Pharma”, acquainted the audience with its technology. According to him, Russian population is among the leaders in the consumption of dietary supplements around the world. According to the results of first 10 months of 2020, the global sales of dietary supplements exceeded $1 billion. “Our technology allows a person to modify the crystal lattice of a substance, which leads to a change in its properties,” the speaker explained. “PolymorfPharma” also carries out the co-crystallization technology, which allows combining the action of several active substances. “We analyzed the most popular dietary supplements and found that almost all of them can be upgraded using our technology”, he said.
Mr. Vladimir Volkov presented to the audience the project "Neurolyte Technology" - a combined minimally invasive technology for the treatment of malignant brain tumours with a laser and microcapsules with a chemotherapeutic agent. Every year, 1.5 million primary and secondary cases of this terrible disease are diagnosed in the world. According to the speaker, the existing types of treatment "do not cover all cases and involve risks." Neurolyte Technology works in inoperable cases and does not harm healthy cells.
Mr. Alexey Arshevsky spoke about the creation and production of disinfectants, using ECA technology (Electro-chemical activation) - using electrical installations. Disinfectants allow one to fight Covid, as well as nosocomial infections. According to the speaker, the market for disinfection tools and equipment will grow rapidly in the coming years.
Mr. Robert Vasiliev made a presentation of the project for the diagnosis of COVID-19 and other diseases - "AL-recommender systems for the analysis of medical data, based on a specific neural network aggregate." According to him, a doctor spends up to 40 minutes diagnosing an MRI or CT scan - this system can reduce this time to 1.5 minutes.
Mr. Ivan Rusanov spoke about the “Med Test Presice” project, which makes it possible to identify laboratories with inaccurate Covid diagnostics (in Russia and the USA, there are about 40% of such laboratories and subsequent results) and to improve their accuracy.
At the end of the event , Mr. Artyom Dalevich, thanked all the participants and reminded that in the months of March and April, the industry investment sessions are scheduled for every two weeks.
The event was moderated by Mr. Sergey Orekhanov, the venture partner of the “YellowRockets” fund, founder of the “Investment Networking Club”, and director of the “Association of Innovative and Venture Capital Financiers”.